About NEXTBIOMEDICAL
NEXTBIOMEDICAL is a company based in Incheon (South Korea) founded in 2014. NEXTBIOMEDICAL operates in a competitive market with competitors including Insulet, Lyra Therapeutics, TriSalus Life Sciences, Credence MedSystems and MiNA Therapeutics, among others.
- Headquarter Incheon, South Korea
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
- Legal Name Nextbiomedical Co., Ltd.
-
Annual Revenue
$6.47 M (USD)95.46as on Dec 31, 2024
-
Net Profit
$1.94 M (USD)0as on Dec 31, 2024
-
EBITDA
-$2.09 M (USD)35.23as on Dec 31, 2024
-
Latest Funding Round
Not available
-
Investors
Not available
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of NEXTBIOMEDICAL
Detailed funding history for NEXTBIOMEDICAL
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by NEXTBIOMEDICAL
Investment portfolio details for NEXTBIOMEDICAL
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - NEXTBIOMEDICAL
Detailed financials for NEXTBIOMEDICAL
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nextbiomedical Comparisons
Peer comparison for NEXTBIOMEDICAL
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of NEXTBIOMEDICAL
NEXTBIOMEDICAL operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insulet, Lyra Therapeutics, TriSalus Life Sciences, Credence MedSystems and MiNA Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Wearable insulin infusion systems are developed for diabetes patients.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for ENT diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of drug delivery devices to treat cancers
|
|
| Locked | Locked | Locked |
Developer of smart devices for drug delivery
|
|
| Locked | Locked | Locked |
Small activating RNA therapeutics are developed to restore gene function.
|
|
| Locked | Locked | Locked |
Injectables and NCEs for cancer and chronic diseases are developed.
|
Detailed competitors of NEXTBIOMEDICAL
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nextbiomedical
Complete news archive for NEXTBIOMEDICAL
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NEXTBIOMEDICAL
NEXTBIOMEDICAL was founded in 2014.
NEXTBIOMEDICAL is headquartered in Incheon, South Korea.
Lee Don Haeng is the current CEO of NEXTBIOMEDICAL.
Annual revenue of NEXTBIOMEDICAL is $6.47M as on Dec 31, 2024.
NextBiomedical manufactures drugs and delivery systems for wound dressing for gastrointestinal bleeding. The product Nexpowder designed for endoscopic hemostasis and ulcer protection after gastrointestinal bleeding or endoscopic procedures. Nexsphere is a polymeric microparticle that is inserted into blood vessels, performs the hemostatic effect and blocks the nutritional sources of abnormal tissues or induce tumor necrosis which helps in detection for cancer. NEXENT is a targeting therapeutic material.
NEXTBIOMEDICAL's top competitors include Insulet, MiNA Therapeutics and Lyra Therapeutics.